GlycoMimetics Names Harout Semerjian as New Chief Executive Officer to Succeed Retiring CEO Rachel King

Published on :

Mr. Semerjian is a global biopharmaceutical veteran. Over the last 25 years, he acquired extensive US, European and international commercialization experience having led multiple successful hematology/oncology product launches, including preparation for the launch of midostaurin in AML.